Market Cap 19.40M
Revenue (ttm) 0.00
Net Income (ttm) -26.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 105,000
Avg Vol 237,830
Day's Range N/A - N/A
Shares Out 14.81M
Stochastic %K 5%
Beta -1.85
Analysts Sell
Price Target $11.00

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
joeyknowie
joeyknowie Jun. 4 at 11:56 PM
$TPST a lot of moves being made. What they might mean remains to be seen.
0 · Reply
TwongStocks
TwongStocks Jun. 4 at 9:35 PM
$TPST Did a comparison of Independent Director Compensation that was in the 10-K and the amended compensation reported in today's filing: • Base retainer reduced from $40K to $20K • Board Chair retainer reduced from $35K to $17.5K • Audit committee Chair reduced from $20K to $10K. Audit committee member reduced from $10K to $5K. • Compensation committee Chair reduced from $15K to $7.5K. Member reduced from $7.5K to $3.75K. • Nominating and Corporate Governance Chair reduced from $10K to $5K. Member reduced from $5K to 2.5K. • Science & Technology committee Chair reduced from $12K to $6K. Member reduced from $6K to $3K. Retainers for independent board members were cut in half. I wonder if that is how Angel got all the Board members to resign.
1 · Reply
TwongStocks
TwongStocks Jun. 4 at 9:18 PM
$TPST Both new Directors were granted 25,000 options. Initial Form 3/4 filings will be made within 2 business days to disclose those transactions. Amended base compensation for independent Directors: a base retainer of $20,000 for service on the Board, an additional $17,500 for service as non-executive Chair of the Board, committee chair retainers of $10,000 for the Audit Committee, $7,500 for the Compensation Committee, $5,000 for the Nominating and Corporate Governance Committee and $6,000 for the Science and Technology Committee, and committee member retainers of $5,000 for the Audit Committee, $3,750 for the Compensation Committee, $2,500 for the Nominating and Corporate Governance Committee and $3,000 for the Science and Technology Committee.
0 · Reply
Onedaytolive
Onedaytolive Jun. 4 at 9:16 PM
$TPST John Yee, MD, MPH Dr. John Yee is a well-known veteran in pharmaceutical development and medical affairs. Key Career Highlights: • Former Head of Medical Affairs at AstraZeneca • Former executive at Genzyme • Former senior executive at Vertex Pharmaceuticals • Former Chief Medical Officer at Sobi North America • Currently SVP of Medical Affairs at Apnimed, a company specializing in sleep apnea treatments Additionally, • Graduate of Harvard Medical School • Holds an MPH from the Harvard T.H. Chan School of Public Health • Over 25 years of experience in pharmaceutical development • Involved in the launch of over 10 new drugs and indications These are his achievements.
1 · Reply
TwongStocks
TwongStocks Jun. 4 at 9:11 PM
$TPST Housecleaning continues. Nicholas Maestas resigns as CFO. Justin Trojanowski promoted from Corporate Controller to Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312526257684/d91703d8k.htm On May 29, 2026, Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026. Filing also confirms the appointments of Dr. John David Yee and Mr. William Drake Richey to the Board (previously reported in this afternoon's PR). With regard to the NASDAQ deficiency notice for Board requirements, TPST "believes it has only one remaining vacancy to fill before becoming eligible for the cure period provided in Nasdaq’s Listing Rules." They intend to make one more independent Board appointment, to satisfy NASDAQ's requirements.
0 · Reply
Michl2000
Michl2000 Jun. 4 at 9:02 PM
$TPST Brady & Co. had to give up as they realized, nobody was interested in TPST-1120 or TPST-1495.
1 · Reply
Michl2000
Michl2000 Jun. 4 at 8:58 PM
$TPST nothing but senseless shit ciming from this company. Forget about the invested money. Already lost the main part and we'll lose the rest too.
0 · Reply
Michl2000
Michl2000 Jun. 4 at 8:54 PM
$TPST 💩💩💩
0 · Reply
focafoca99
focafoca99 Jun. 4 at 8:53 PM
$TPST installed two new independent directors, Drake Richey and John Yee, to boost its CAR‑T leadership.
1 · Reply
TwongStocks
TwongStocks Jun. 4 at 8:48 PM
$TPST Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors https://ir.tempesttx.com/news-releases/news-release-details/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph
0 · Reply
Latest News on TPST
Tempest Therapeutics Proxy statement: Proxy filing

May 29, 2026, 8:00 AM EDT - 6 days ago

Tempest Therapeutics Proxy statement: Proxy filing


Tempest Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 21 days ago

Tempest Therapeutics Earnings release: Q1 2026


Tempest Therapeutics Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 21 days ago

Tempest Therapeutics Quarterly report: Q1 2026


Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 4 weeks ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting


Tempest Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 4 weeks ago

Tempest Therapeutics Slides: Corporate presentation


Tempest Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 2 months ago

Tempest Therapeutics Annual report: Q4 2025


Tempest Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 2 months ago

Tempest Therapeutics Earnings release: Q4 2025


Tempest Therapeutics Registration statement: Registration filing

Mar 30, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Registration statement: Registration filing


Tempest Therapeutics Proxy statement: Proxy Filing

Dec 31, 2025, 7:00 AM EST - 5 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Dec 2, 2025, 7:00 AM EST - 6 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Nov 19, 2025, 7:00 AM EST - 7 months ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 7 months ago

Tempest Therapeutics Quarterly report: Q3 2025


Tempest Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 9:00 AM EST - 7 months ago

Tempest Therapeutics Earnings release: Q3 2025


Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

2025-11-05T13:36:56.000Z - 7 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year


Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

2025-08-11T20:55:19.000Z - 10 months ago

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)


Tempest Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Tempest Therapeutics Quarterly report: Q2 2025


Tempest Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Tempest Therapeutics Earnings release: Q2 2025


Tempest Therapeutics receives ODD from EMA for amezalpat

2025-06-05T12:05:21.000Z - 1 year ago

Tempest Therapeutics receives ODD from EMA for amezalpat


Tempest Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q1 2025


Tempest Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q1 2025


Tempest Therapeutics announces FDA granted ODD to TPST-1495

2025-04-21T12:08:31.000Z - 1 year ago

Tempest Therapeutics announces FDA granted ODD to TPST-1495


Tempest Therapeutics Slides: Corporate Presentation

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Slides: Corporate Presentation


Tempest Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Annual report: Q4 2024


Tempest Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q4 2024


Tempest Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Earnings release: Q3 2024


Tempest Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Quarterly report: Q3 2024


Tempest Therapeutics Proxy statement: Proxy Filing

Nov 12, 2024, 7:00 AM EST - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q2 2024


Tempest Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q2 2024


Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update


Tempest Therapeutics Slides: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Slides: Study Update


Tempest Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q1 2024


Tempest Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q1 2024


Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing


Tempest Therapeutics Earnings release: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q4 2023


Tempest Therapeutics Annual report: Q4 2023

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Annual report: Q4 2023


Tempest Therapeutics Slides: Corporate Presentation

Nov 20, 2023, 5:00 AM EST - 2 years ago

Tempest Therapeutics Slides: Corporate Presentation


Tempest Therapeutics Quarterly report: Q3 2023

Nov 8, 2023, 4:00 PM EST - 2 years ago

Tempest Therapeutics Quarterly report: Q3 2023


Tempest Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 4:00 PM EST - 2 years ago

Tempest Therapeutics Earnings release: Q3 2023


Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop


Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain


joeyknowie
joeyknowie Jun. 4 at 11:56 PM
$TPST a lot of moves being made. What they might mean remains to be seen.
0 · Reply
TwongStocks
TwongStocks Jun. 4 at 9:35 PM
$TPST Did a comparison of Independent Director Compensation that was in the 10-K and the amended compensation reported in today's filing: • Base retainer reduced from $40K to $20K • Board Chair retainer reduced from $35K to $17.5K • Audit committee Chair reduced from $20K to $10K. Audit committee member reduced from $10K to $5K. • Compensation committee Chair reduced from $15K to $7.5K. Member reduced from $7.5K to $3.75K. • Nominating and Corporate Governance Chair reduced from $10K to $5K. Member reduced from $5K to 2.5K. • Science & Technology committee Chair reduced from $12K to $6K. Member reduced from $6K to $3K. Retainers for independent board members were cut in half. I wonder if that is how Angel got all the Board members to resign.
1 · Reply
TwongStocks
TwongStocks Jun. 4 at 9:18 PM
$TPST Both new Directors were granted 25,000 options. Initial Form 3/4 filings will be made within 2 business days to disclose those transactions. Amended base compensation for independent Directors: a base retainer of $20,000 for service on the Board, an additional $17,500 for service as non-executive Chair of the Board, committee chair retainers of $10,000 for the Audit Committee, $7,500 for the Compensation Committee, $5,000 for the Nominating and Corporate Governance Committee and $6,000 for the Science and Technology Committee, and committee member retainers of $5,000 for the Audit Committee, $3,750 for the Compensation Committee, $2,500 for the Nominating and Corporate Governance Committee and $3,000 for the Science and Technology Committee.
0 · Reply
Onedaytolive
Onedaytolive Jun. 4 at 9:16 PM
$TPST John Yee, MD, MPH Dr. John Yee is a well-known veteran in pharmaceutical development and medical affairs. Key Career Highlights: • Former Head of Medical Affairs at AstraZeneca • Former executive at Genzyme • Former senior executive at Vertex Pharmaceuticals • Former Chief Medical Officer at Sobi North America • Currently SVP of Medical Affairs at Apnimed, a company specializing in sleep apnea treatments Additionally, • Graduate of Harvard Medical School • Holds an MPH from the Harvard T.H. Chan School of Public Health • Over 25 years of experience in pharmaceutical development • Involved in the launch of over 10 new drugs and indications These are his achievements.
1 · Reply
TwongStocks
TwongStocks Jun. 4 at 9:11 PM
$TPST Housecleaning continues. Nicholas Maestas resigns as CFO. Justin Trojanowski promoted from Corporate Controller to Vice President, Finance, Principal Financial Officer and Corporate Secretary of the Company. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001544227/000119312526257684/d91703d8k.htm On May 29, 2026, Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026. Filing also confirms the appointments of Dr. John David Yee and Mr. William Drake Richey to the Board (previously reported in this afternoon's PR). With regard to the NASDAQ deficiency notice for Board requirements, TPST "believes it has only one remaining vacancy to fill before becoming eligible for the cure period provided in Nasdaq’s Listing Rules." They intend to make one more independent Board appointment, to satisfy NASDAQ's requirements.
0 · Reply
Michl2000
Michl2000 Jun. 4 at 9:02 PM
$TPST Brady & Co. had to give up as they realized, nobody was interested in TPST-1120 or TPST-1495.
1 · Reply
Michl2000
Michl2000 Jun. 4 at 8:58 PM
$TPST nothing but senseless shit ciming from this company. Forget about the invested money. Already lost the main part and we'll lose the rest too.
0 · Reply
Michl2000
Michl2000 Jun. 4 at 8:54 PM
$TPST 💩💩💩
0 · Reply
focafoca99
focafoca99 Jun. 4 at 8:53 PM
$TPST installed two new independent directors, Drake Richey and John Yee, to boost its CAR‑T leadership.
1 · Reply
TwongStocks
TwongStocks Jun. 4 at 8:48 PM
$TPST Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors https://ir.tempesttx.com/news-releases/news-release-details/tempest-therapeutics-appoints-drake-richey-and-john-yee-md-mph
0 · Reply
lousjamsession
lousjamsession Jun. 4 at 7:57 PM
0 · Reply
Xamayca
Xamayca Jun. 4 at 7:38 PM
$TPST Green all day can it finally stabilize?
0 · Reply
josegodoy
josegodoy Jun. 4 at 7:18 PM
$TPST you see TPST’ problem is it hasn’t had any money for a very long time (Roche standard of care supply for a PIII wasn’t a bad deal (if they had money)). VERU “Veru will sponsor and run the Phase 2b study, while Novo Nordisk will supply Wegovy at no charge for use solely within the trial. Veru will share trial design insights, methodology, and ongoing safety and protocol updates with Novo Nordisk. “ https://www.stocktitan.net/sec-filings/VERU/8-k-veru-inc-reports-material-event-65485ec2d0c3.html
0 · Reply
Michl2000
Michl2000 Jun. 4 at 6:14 PM
$TPST great, 1ct up 🥳. But $SLS still a little better 🤷
1 · Reply
Michl2000
Michl2000 Jun. 4 at 1:50 PM
$TPST direct bnkrptcy of the "old" TPST would habe been the much better choice compared to this ridiculous factor deal and what's happening now 😏
0 · Reply
Michl2000
Michl2000 Jun. 4 at 1:43 PM
$TPST or rather preparing for bnkrptcy 🤔???
0 · Reply
Michl2000
Michl2000 Jun. 4 at 12:43 PM
$TPST barcoding 😁😁😁
0 · Reply
Xamayca
Xamayca Jun. 4 at 11:09 AM
$TPST Realistically what does a 50 mil sale whic implies $3-4 per share do in terms of unlocking CAR-T value by virus of the face that cash starvation is averted for the foreseeable future with CAR-T research largely funded? Does the market price a premium on top of the cash I would think a few dollars at least $2-3 more thoughts anyone?
1 · Reply
joeyknowie
joeyknowie Jun. 4 at 11:06 AM
$TPST not necessarily imo bc this is how they scare retail and also Sanby is involved again so who knows when they are around it seems strange things happen
1 · Reply
Xamayca
Xamayca Jun. 4 at 11:01 AM
$TPST What’s frightening is that this hasn’t moved up at all !? Even if there was a deal coming for 50 mil there should be a bottom and reversal beforehand
0 · Reply
joeyknowie
joeyknowie Jun. 4 at 5:43 AM
$TPST for all the board other than Angel to go is an interesting development. Is it possible there’s a deal on the table for $50 million or so for the legacy assets and Brady and his cronies wouldn’t go for it? Angel is the boss now and it wouldn’t surprise me if there was an ouster over lack of agreement on value of legacy assets. Under the Brady regime this company had a value over one billion dolllars at one point. Think about that. And now the market cap is at $20 million roughly. It would be easy to see psychologically how even $100 million deal would be insulting to Brady and crew but we are here in the present not at the time where opportunity was squandered. I mean I get hindsight is clearer but $1 billion compared to now where you are on the street basically. I feel bad for you. $50 head anyone? What a disaster. I’m glad Brady is gone even though I think he is a good well intentioned guy. Hopefully genius Angel can extract value from the mess Brady seems to have made.
4 · Reply
Michl2000
Michl2000 Jun. 3 at 8:46 PM
$TPST 🤦
0 · Reply